Immatics (IMTX) Net Income towards Common Stockholders (2019 - 2025)

Immatics' (IMTX) quarterly Net Income towards Common Stockholders came in at -$46.2 million in Q4 2025, down 188.04% year-on-year from $52.5 million in Q4 2024, and up 22.23% quarter-over-quarter from -$59.4 million in Q3 2025.

Immatics (IMTX) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends

Immatics has disclosed Net Income towards Common Stockholders across 7 years of filings, most recently posting -$46.2 million for Q4 2025.

  • Net Income towards Common Stockholders for Q4 2025 came in at -$46.2 million, down 188.04% year-over-year; the trailing twelve-month figure through Dec 2025 was -$229.4 million (down 1520.9% YoY), and the FY2025 annual result was -$221.9 million, down 1464.84% from the prior year.
  • Net Income towards Common Stockholders came in at -$46.2 million for Q4 2025 at Immatics, up from -$59.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $96.1 million in Q1 2022 to a low of -$81.9 million in Q2 2025.
  • The 5-year median for Net Income towards Common Stockholders is -$23.4 million (2023), against an average of -$18.0 million.
  • Across the five-year window, Net Income towards Common Stockholders jumped 449.38% in 2022 and plunged 1232.27% in 2023, its largest moves.
  • Immatics' Net Income towards Common Stockholders stood at -$19.2 million in 2021, then soared by 111.78% to $2.3 million in 2022, then plunged by 1232.27% to -$25.6 million in 2023, then jumped by 304.83% to $52.5 million in 2024, then tumbled by 188.04% to -$46.2 million in 2025.
  • The last three Net Income towards Common Stockholders figures came in at -$46.2 million (Q4 2025), -$59.4 million (Q3 2025), and -$81.9 million (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.56 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 2.50 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.63 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Immatics 14.67 Bn 14.67 Bn - -46.18 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -46.18 Mn
Sep 30, 2025 -59.39 Mn
Jun 30, 2025 -81.90 Mn
Mar 31, 2025 -41.92 Mn
Dec 31, 2024 52.46 Mn
Sep 30, 2024 -13.62 Mn
Jun 30, 2024 -19.38 Mn
Mar 31, 2024 -3.32 Mn
Dec 31, 2023 -25.61 Mn
Sep 30, 2023 -28.84 Mn
Jun 30, 2023 -26.80 Mn
Mar 31, 2023 -21.20 Mn
Dec 31, 2022 2.26 Mn
Sep 30, 2022 -19.98 Mn
Jun 30, 2022 -12.47 Mn
Mar 31, 2022 96.14 Mn
Dec 31, 2021 -19.20 Mn
Sep 30, 2021 -32.08 Mn
Jun 30, 2021 -31.95 Mn
Mar 31, 2021 -27.52 Mn